Multifunctional Lipid-Based Nanoparticles for Codelivery of Anticancer Drugs and siRNA for Treatment of Non-Small Cell Lung Cancer with Different Level of Resistance and EGFR Mutations

Multifunctional Lipid-Based Nanoparticles for Codelivery of Anticancer Drugs and siRNA for Treatment of Non-Small Cell Lung Cancer with Different Level of Resistance and EGFR Mutations

Resistance to chemotherapy, enhanced proliferation, invasion, angiogenesis, and metastasis (RPIAM) represent major obstacles that limit the efficacy of cancer treatment especially in advanced stages of cancer. Overcoming or suppressing RPIAM can dramatically improve the treatment outcome. Non-small...

Full description

Bibliographic Details
Main Authors: Joydeb Majumder, Tamara Minko
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Pharmaceutics
Subjects:
EGFR mutated and gefitinib-resistant NSCLC
lipid nanoparticles
siRNA
LHRH
paclitaxel
Online Access:https://www.mdpi.com/1999-4923/13/7/1063

Internet

https://www.mdpi.com/1999-4923/13/7/1063

Similar Items